A5029354324- Acute Myocardial Infarction Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Coronary Interventions and Diagnostics
- Cardiac Imaging and Diagnostics
- Atrial Fibrillation Management and Outcomes
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Academic Writing and Publishing
- Venous Thromboembolism Diagnosis and Management
- Health and Medical Research Impacts
- Meta-analysis and systematic reviews
- Acute Ischemic Stroke Management
- scientometrics and bibliometrics research
- Cardiac, Anesthesia and Surgical Outcomes
- Lipoproteins and Cardiovascular Health
- Acute Kidney Injury Research
- Peripheral Artery Disease Management
- Vitamin K Research Studies
- Health Systems, Economic Evaluations, Quality of Life
- Traumatic Brain Injury and Neurovascular Disturbances
- Medication Adherence and Compliance
- Mast cells and histamine
- Spinal Hematomas and Complications
- Signaling Pathways in Disease
- Statistical Methods in Clinical Trials
- Blood Coagulation and Thrombosis Mechanisms
University of Catania
2022-2025
Policlinico Universitario di Catania
2022-2025
Florida College
2025
University of Florida
2025
Ingegneria dei Trasporti (Italy)
2023
The evolution of anticoagulation therapy, from vitamin K antagonists to the advent direct oral anticoagulants (DOACs) almost two decades ago, marks significant progress. Despite improved safety demonstrated in pivotal trials and post-marketing observations, persistent concerns exist, particularly regarding bleeding risk absence therapeutic indications specific subgroups or clinical contexts. Factor XI (FXI) has recently emerged as a contributor intraluminal thrombus formation growth, playing...
Abstract Background and aims Multiple anti-inflammatory drugs have been tested for secondary prevention after myocardial infarction (MI), giving mixed results questioning the efficacy of therapy. No head-to-head comparisons between performed. This study aimed to compare safety MI relative merits specific administration strategies. Methods Randomized trials therapy were identified. Primary endpoints trial-defined major adverse cardiovascular events (MACE) serious events. Secondary included...
Background Intracoronary provocation testing with acetylcholine (ACh) is helpful to diagnose and risk‐stratify patients ischemia nonobstructed coronary arteries (NOCA) myocardial infarction NOCA. This study explored potential sex‐related disparities on the prognostic significance of ACh provocative testing. Methods Consecutive NOCA those who underwent were enrolled. The primary end point was incidence major adverse cardiovascular cerebrovascular events at follow‐up. Co‐primary points angina...
Noninferiority trials are increasingly common in cardiovascular medicine, but their reporting and interpretation challenging, particularly when an absolute risk difference is used as noninferiority margin.
Abstract Periprocedural myocardial infarction (PMI) and injury, pertinent to both cardiac non-cardiac procedures, have gained increasing recognition in clinical practice. Over time, diverse definitions for diagnosing PMI been developed validated among patient populations undergoing coronary revascularization. However, this variety presents considerable challenges settings complicates the design interpretation of trials. The necessity accurately diagnose has spurred significant interest...
Background – Although Factor XI (FXI) inhibitors are currently tested for the prevention of thrombotic events, their early treatment could prevent thrombus consolidation in ST-segment elevation myocardial infarction (STEMI). This study aims to characterize coagulation FXI levels and variations patients with STEMI undergoing primary percutaneous coronary intervention (PCI). Methods Patients were prospectively enrolled between December 2023 May 2024. activity (FXIa) measured at admission after...
Single antiplatelet therapy (SAPT) and intensified antithrombotic regimens (prolonged dual [DAPT] or pathway inhibition [DPI]) are recommended for secondary prevention in patients who underwent percutaneous coronary intervention (PCI) after initial DAPT. We aimed to characterize eligibility such strategies explore what extent guidelines applied clinical practice. Patients PCI acute chronic syndrome completed DAPT were analyzed from a prospective registry. categorized into SAPT, prolonged...
Clinical trials, essential for medical advancement, vary significantly in methodology and regulatory pathways depending on the type of therapeutic intervention (i.e., drugs or devices). This study aimed to determine whether drug device types influence impact randomized trials cardiovascular medicine. We analyzed late-breaking controlled presented at major cardiology conferences from 2015 2021. The primary endpoint was total number citations obtained. Secondary endpoints included 1 2 years,...
Women and older patients are underrepresented in randomized controlled trials (RCTs) investigating treatment strategies following acute coronary syndrome. This study aims to evaluate the benefit of invasive vs. conservative strategy women with non-ST-elevation syndrome (NSTEACS).